VivoSeq
Psychiatry

Methamphetamine Use

0

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Methamphetamine Use is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

14/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Recruiting2 · 29%
Terminated1 · 14%

Clinical Trials

Trial Activity

7 trials

Creatine for Depressed Male and Female Methamphetamine Users
Recruiting·—·Phase 3·NCT02568878·29 enrolled
PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)
Recruiting·UUniversity of Utah·Phase 1·NCT05128071·40 enrolled
Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors
Completed·SSan Francisco Department of Public Health·Phase 2·NCT00497081·60 enrolled
Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade
Completed·OOregon Health and Science University·N/A·NCT01822132·76 enrolled
A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users
Completed·—·Phase 4·NCT02192931·65 enrolled
Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users
Completed·VVA Office of Research and Development·Phase 2·NCT03341078·176 enrolled
Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users
Terminated·UUniversity of California, Los Angeles·Phase 1·NCT03059563·62 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)